Literature DB >> 30954637

Exploring the interoceptive stimulus effects of nicotine and varenicline.

Brady M Thompson1, Scott T Barrett1, Rick A Bevins2.   

Abstract

Learning processes associated with nicotine influence the development of addiction to tobacco products. In the present report, we are interested in the interoceptive stimulus effects of nicotine acquiring control over appetitive behaviors - specifically, reward seeking. Also of interest is the current smoking cessation drug, varenicline (Chantix®). Varenicline, with its nicotine-like stimulus effects, can decrease withdrawal and cravings for a subset of individuals addicted to nicotine, though relapse is still common. We trained rats (N = 48) with nicotine (0.4 mg/kg, SC) as an excitatory stimulus (i.e., paired with sucrose) in a drug-discriminated goal-tracking (DGT) task. There was no access to sucrose on interspersed saline days. After acquisition of the initial nicotine-saline discrimination, rats were separated into four groups to test discrimination reversal and drug substitution. The control group maintained nicotine as the excitatory stimulus (NIC+). The substitution group had varenicline (1 mg/kg) replace nicotine as the stimulus paired with sucrose (VAR+). One reversal group had nicotine signal the absence of sucrose (i.e., now available on intermixed saline sessions; NIC-). The last group was similar to the NIC- group except varenicline replaced nicotine on non-reinforced sessions (VAR-). We found that varenicline fully substituted as the training stimulus when the drug-sucrose relation remained in place (VAR+). Both reversal groups acquired the new discrimination, albeit slowly and more variable for the VAR- group in comparison to NIC-. There was an effect of group during substitution testing. Specifically, nicotine fully substituted for varenicline regardless of condition. However, varenicline only partially substituted for the nicotine stimulus. At the start of extinction, responding mimicked that of the rats training condition. However, by extinction session 12, all groups maintained similarly low levels of responding. These findings show nicotine and varenicline share stimulus elements, yet the conclusion of partial to full substitution depends on the nature of the testing protocol.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chantix®; Drug discrimination; Nicotine; Pavlovian conditioning; Reversal learning; Varenicline

Mesh:

Substances:

Year:  2019        PMID: 30954637      PMCID: PMC6545145          DOI: 10.1016/j.pbb.2019.04.001

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  40 in total

1.  Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression.

Authors:  R A Bevins; J Besheer; K S Pickett
Journal:  Pharmacol Biochem Behav       Date:  2001-01       Impact factor: 3.533

2.  Discriminative control of variability: effects of successive stimulus reversals.

Authors:  Ryan D Ward; Adam D Kynaston; Ericka M Bailey; Amy L Odum
Journal:  Behav Processes       Date:  2007-12-03       Impact factor: 1.777

3.  Patterns of nicotinic receptor antagonism: nicotine discrimination studies.

Authors:  Emily M Jutkiewicz; Emily A Brooks; Adam D Kynaston; Kenner C Rice; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2011-07-05       Impact factor: 4.030

4.  Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.

Authors:  Sungwon Roh; Susanne S Hoeppner; David Schoenfeld; Catherine A Fullerton; Luke E Stoeckel; A Eden Evins
Journal:  Psychopharmacology (Berl)       Date:  2013-10-11       Impact factor: 4.530

Review 5.  Interoception and learning: import to understanding and treating diseases and psychopathologies.

Authors:  Rick A Bevins; Joyce Besheer
Journal:  ACS Chem Neurosci       Date:  2014-07-22       Impact factor: 4.418

Review 6.  Disentangling the nature of the nicotine stimulus.

Authors:  Rick A Bevins; Scott T Barrett; Robert J Polewan; Steven T Pittenger; Natashia Swalve; Sergios Charntikov
Journal:  Behav Processes       Date:  2011-11-24       Impact factor: 1.777

7.  Nicotine does not produce state-dependent effects on learning in a Pavlovian appetitive goal tracking task with rats.

Authors:  Rick A Bevins; Rachel D Penrod; Carmela M Reichel
Journal:  Behav Brain Res       Date:  2006-11-28       Impact factor: 3.332

8.  Dissociable contributions of the orbitofrontal and infralimbic cortex to pavlovian autoshaping and discrimination reversal learning: further evidence for the functional heterogeneity of the rodent frontal cortex.

Authors:  Y Chudasama; Trevor W Robbins
Journal:  J Neurosci       Date:  2003-09-24       Impact factor: 6.167

Review 9.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

Authors:  Kate Cahill; Sarah Stevens; Rafael Perera; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

10.  Acquisition, extinction, recovery, and reversal of different response sequences under conditional control by nicotine in rats.

Authors:  Joseph R Troisi
Journal:  J Gen Psychol       Date:  2013 Jul-Sep
View more
  3 in total

1.  Understanding the stimulus effects of nicotine and bupropion in a drug-drug discriminated goal-tracking task.

Authors:  Andrea E Moran; Y Wendy Huynh; Andrew P Finkner; Carly Selleck; Aelyn Thompson; Scott T Barrett; Rick A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2022-02-09       Impact factor: 4.530

2.  The importance of acquisition learning on nicotine and varenicline drug substitution in a drug-discriminated goal-tracking task.

Authors:  Brady M Thompson; Scott T Barrett; Y Wendy Huynh; David A Kwan; Jennifer E Murray; Rick A Bevins
Journal:  Pharmacol Biochem Behav       Date:  2020-10-12       Impact factor: 3.533

3.  Chronic nicotine increases alcohol self-administration in adult male Wistar rats.

Authors:  Christian Montanari; Maria E Secci; Ashlyn Driskell; Katherine O McDonald; Connor L Schratz; Nicholas W Gilpin
Journal:  Psychopharmacology (Berl)       Date:  2020-09-30       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.